Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses hair loss treatments, specifically the use of finasteride, dutasteride, and RU58841. The user is seeking alternatives after finasteride failed to stop hair loss, with suggestions to try dutasteride or consider RU58841 under caution.

Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.

The user is experiencing severe hair thinning and is using multiple treatments including topical finasteride, minoxidil, tretinoin, latanoprost, oral minoxidil, dutasteride, saw palmetto, and derma wounding. They are considering adding RU58841 and are contemplating a hair transplant and exosomes due to frustration with current results.

KX-826 failed Phase III trials due to high placebo effects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.

The user has been experiencing hair loss for over 5 years and is currently using a topical treatment of finasteride, minoxidil, and tretinoin, along with derma rolling and a hair growth oil. They have previously tried oral finasteride, pyrithione zinc, RU58841, and dutasteride, but are seeking advice on whether to retry dutasteride or find a more reliable source for RU58841 due to ongoing hair density loss.

RU58841 hasn't stopped shedding for the user after three weeks, despite being stable on dutasteride for six years. Suggestions include continuing RU58841 for 4-6 months, considering minoxidil, and addressing stress and sleep issues.

The user shared progress pictures showing crown recovery after 8 months of using 1mg finasteride, 2mg minoxidil, and 2% ketoconazole shampoo. They noted significant hair texture changes and are hopeful for temple recovery.

The user has been on a hair loss treatment for 14 months using dutasteride and oral minoxidil without seeing regrowth and is considering adding more drugs due to the psychological impact of hair loss. However, replies suggest the user may not actually be experiencing noticeable hair loss.

Finasteride is not linked to a 60% risk of persistent sexual dysfunction; this figure applies only to those already experiencing sexual issues. Most users do not have side effects, and the study's methodology is criticized for selection bias.

The user is frustrated with the delayed delivery of their Pryiltamide order from Koshine. They mention the order was shipped on August 23 but have received no updates since.

A young female diagnosed with Lichen planopilaris (LPP) experienced years of misdiagnosis and ineffective treatments, including a hair transplant and other procedures. She is considering litigation due to the misdiagnosis and has learned that LPP is chronic, hair loss can be stopped with ongoing medication, but lost hair cannot regrow.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

The user experienced severe side effects with topical finasteride, continued using Minoxidil, and was advised to try topical dutasteride after a test suggested they might not respond to finasteride. They are hesitant to start the new treatment due to past side effects.

The user experienced hair loss after chikungunya and started PRF (platelet-rich fibrin) injections with injectable Dutasteride, noticing new hair growth. They are hopeful for continued improvement.

The conversation discusses Breezula, a hair loss treatment, and its Phase 3 clinical trial recruitment at 50 locations. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

The user initially had success with Minoxidil for hair loss but stopped due to life changes, resulting in hair loss returning. They plan to restart treatment with Minoxidil, add Nizoral, dermarolling, and supplements like saw palmetto and beta-sitosterol, while avoiding pharmaceutical drugs.

The user reported significant hair improvement over 15 months using dutasteride, minoxidil (oral and topical), RU58841, ketoconazole, and microneedling. They are considering a hair transplant in 4-6 months.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

The user experienced severe hair shedding from RU58841 and recovered by stopping its use and starting treatments including Minoxidil, Rosemary Verbenone, Stemoxydine, Aminexil, copper peptide serum, and specific shampoos. They also consistently used oral Finasteride and plan to try Minoxidil 10%.

The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.

A user experienced no hair regrowth after using oral minoxidil, topical finasteride, minoxidil, and tretinoin, and reported side effects from oral finasteride. They are considering switching to dutasteride or using hair fibers for better results.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.

A 22.5-year-old male is frustrated with doctors for not taking his diffuse thinning seriously. He has been using finasteride for 2.5 years, avoids topical minoxidil due to dandruff, and is hesitant about oral minoxidil due to weight and injury concerns.

The Shiseido/Replicel RCH-01 trial results were disappointing and ineffective. Users expressed skepticism and frustration, suggesting alternatives like Tsuji or simply accepting baldness.

Hair loss discussion includes treatments Min, Fin, and RU. Kintor's KX-826 Phase 2 data release delayed to September due to COVID.

A user's 14 month experience with Dutasteride for hair loss and other users discussing their experiences with Dutasteride, Minoxidil, Finasteride, and RU58841.

The user is using RU58841, dutasteride, and minoxidil for hair loss, storing RU58841 in the fridge and applying it nightly. They report more baby hairs on the temples but are unsure if it's due to new growth or miniaturization, and seek advice on mixing and results from RU58841.

The user is using oral Minoxidil, oral Dutasteride, microneedling, and RU58841 for hair loss, noticing slow progress with small hairs appearing. They are inconsistent with microneedling frequency, sometimes doing it weekly or skipping weeks.

A clinical trial for Verteporfin as a hair loss treatment, and the potential for greater progress in treatments for hair loss in the future. Common treatments such as Minoxidil, Finasteride and RU58841 were discussed.

The conversation is about incorporating tretinoin into a hair loss regimen after using minoxidil and finasteride for years, with discussions on the effectiveness of minoxidil and the potential benefits of adding tretinoin. Users also discuss the effectiveness of oral minoxidil and other topical treatments like diclofenac and fluocinolone.